Vanguard Group Inc Zymeworks Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.65 - $7.43 $384,587 - $614,513	-82,707 Reduced 13.63%	523,983 $3.22 Million
Q2 2022 Aug 12, 2022	BUY	$4.82 - $7.7 $932,245 - $1.49 Million	193,412 Added 46.8%	606,690 $3.22 Million
Q1 2022 May 13, 2022	BUY	$6.0 - $16.98 $1.08 Million - $3.05 Million	179,461 Added 76.75%	413,278 $2.71 Million
Q4 2021 Feb 14, 2022	BUY	$15.19 - $29.33 $945,744 - $1.83 Million	62,261 Added 36.29%	233,817 $3.83 Million
Q3 2021 Nov 12, 2021	BUY	$27.35 - $37.28 $173,453 - $236,429	6,342 Added 3.84%	171,556 $4.98 Million
Q2 2021 Aug 13, 2021	BUY	$26.5 - $38.23 $4.38 Million - $6.32 Million	165,214 New	165,214 $5.73 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $917M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.